A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
A phase 2 trial of Paclitaxel / nab-paclitaxel in ovarian cancer, run by Shanghai Jiaolian Drug Research and Development Co., Ltd, now recruiting.
Overview
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. is a phase 2 interventional study registered as NCT06434610 by Shanghai Jiaolian Drug Research and Development Co., Ltd, with 90 participants planned, started 2024-07-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: B013, Paclitaxel, Placebo. Conditions listed: Platinum-resistant Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.
Setting
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.
Phase
Phase 2
Sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Registry
Enrolled
90
Similar pages
not linked directly; found by shared links- TrialCATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov
- TrialA Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
- TrialStudy to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax
- TrialA Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
- TrialStudy of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
- TrialOregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
- TrialPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer